Large volume donor plasmapheresis in inherited thrombophilia implicated in arterial thrombosis

Transfusion and Apheresis Science

Volumn 28, Issue 3, 2003, Pages 201-206

  Ovali, Ercüment ^a   Ratip, Siret ^b   Özmenoǧlu, Mehmet ^a   Karti, S Sami ^a   Uçar, Fahri ^a   Ukinç, Kubilay ^a   Yilmaz, Mustafa ^a   Koşucu, Polat ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

MTHFR 677C T; Plasmapheresis; Prothrombin 20210G A; Thrombosis

Indexed keywords

ADULT; ALLELE; APHERESIS; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; BLOOD DONOR; BRAIN INFARCTION; CASE REPORT; FAMILIAL DISEASE; HUMAN; MALE; MUTATION; PLASMAPHERESIS; THROMBOPHILIA; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 0242501561     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-0502(03)00054-5     Document Type: Article

References (34)

1. McLeod B.C., Price T.H., Owen H.et al. Frequency of immediate adverse effects associated with apheresis donation. Transfusion. 38:1998;938-943.
2. Vengelen-Teyler V. Technical manual. fourth ed. 1999;129-148 American Associations of Blood Banks, Bethesda, MA.
3. Gilcher R.O. Apheresis principles and practices. Rossi E.C., Simon T.L., Moss G.S., Gould S.A. Principles of transfusion medicine. fourth ed. 1995;537-546 Williams and Wilkins, Baltimore, MD.
4. Schmitt E., Kundt G., Klinkmann H. Three years with a national apheresis registry. J. Clin. Apheresis. 7:1992;58-62.
5. Araki A., Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. 422:1987;43-52.
6. Miller S.A., Dykes D.D., Poleskey H.F. A simple salting out procedure of extracting DNA from human nucleated cells. Nucleic Acids Res. 16:1988;1215-1219.
7. Wilde J.T., O'Sullivan J.J., Roper J.L.et al. A novel ELISA-based primer extension assay for detection of the factor V leiden mutation. BJH. 1999;427-430.
8. Smith J.W. Donation of red cells and plasma components by apheresis. McLeod B.C., Price T.H., Drew M.J. Apheresis: principles and practice. 1997;211-221 AABB press, Bethesta, MD.
9. Zimmermann B., Scheel H., Wegner H. Thrombophilia in blood-donation for plasma and cytapheresis caused by antithrombin III depletion. Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch. 115:1988;314-318.
10. Flaum M.A., Cuneo R.A., Appelbaum F.R.et al. The hemostatic imbalance of plasma-exchange transfusion. Blood. 54:1979;694-702.
11. Sultan Y., Bussel A., Maisonneuve P.et al. Potential danger of thrombosis after plasma exchange in treatment of patients with immune disease. Transfusion. 19:1979;588-593.
12. Rao A.K., Schneider B., Beckett C.et al. The hemostatic system in children undergoing intensive plasma exchange. J. Pediatr. 100:1982;69-75.
13. Manucci P.M., D'Angelo A., Vigano S.et al. Decrease and rapid recovery of protein C after plasma exchange. Transfusion. 26:1986;156-158.
14. Nilsson T., Rudolphi O., Cedergren B. Effects of intensive plasmapheresis on the haemostatic system. Scand. J. Haematol. 30:1983;201-206.
15. Lane D.A., Grant P.J. Role of hemostatic gene polmorphism in venous and arterial thrombotic disease. Blood. 95:2000;1517-1532.
16. Antoniadi T., Hatzis T., Kroupis C.et al. Prevalance of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in a Greek population of blood donors. Am. J. Hematol. 61:1999;265-267.
17. ′-untranslated region variant (G20210A) and thermolabile methylenetetrahydrofolate reductase (C677T): a single genetic test genotypes all three loci-determination of frequencies in the S.Wales population of the UK. Thromb. Haemost. 79:1998;949-954.
18. Angelopoulou K., Nicolaides A., Constantinou Deltas C. Prevalance of genetic mutations that predispose to thrombophilia in a Greek Cypriot population. Clin. Appl. Thromb. Hemost. 6:2000;104-107.
19. Frosst P., Blom H.J., Milos R.et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10:1995;111-113.
20. Jacques P.F., Bostom A.G., Williams R.R.et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 93:1996;7-9.
21. Gallagher P.M., Meleady R., Shields D.C.et al. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation. 94:1996;2154-2158.
22. Izumi M., Iwai N., Ohmichi N.et al. Molecular variant of 5,10-methylenetetrahydrafolate reductase is a risk factor of ischemic heart disease in the Japanese population. Atherosclerosis. 121:1996;293-294.
23. Kluijtmans L.A., van den Heuvel L.P., Boers G.H.et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am. J. Hum. Genet. 58:1996;35-41.
24. Inbal A., Freimark D., Modan B.et al. Synergistic effects of prothrombotic polymorfisms and atherogenic factors on the risk of myocardial infarction in young males. Blood. 93:1999;2186-2190.
25. Morita H., Taguchi J., Kurihara H.et al. Genetic polymorfism of 5,10-methylenetetrahyrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 95:1997;2032-2036.
26. Zheng Y.Z., Tong J., Do X.P.et al. Prevalence of methylenetetrahydrofolate reductase C677T and its association with arterial and venous thrombosis in the Chinese population. Br. J. Haematol. 109:2000;870-874.
27. Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M. A common genetic variation in the 3-untranslated region of prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 88:1996;3698-3703.
28. Ferraresi P., Marchetti G., Legnani C.et al. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombophilias and is not increased in frequency in arterial disease. Artherioscler. Thromb. Vasc. Biol. 17:1997;2418-2422.
29. Ridker P.M., Hennekens C.H., Miletich J.P. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation. 99:1999;999-1004.
30. Longstreth W.T., Rosendaal F.R., Siscovick D.S.et al. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke. 29:1998;577-580.
31. Rosendaal F.R., Siscovick D.S., Schwartz S.M.et al. A common prothrombin variant (20210G to A) increases the risk of myocardial infarction in young women. Blood. 90:1997;1747-1750.
32. Doggen C.J., Cats V.M., Bertina R.M., Rosendaal F.R. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation. 97:1998;1037-1041.
33. Arkel Y.S., Ku D.H., Gibson D., Lam X. Ischemic stroke in young patient with protein C deficiency and prothrombin gene mutation G20210A. Blood Coagul. Fibrinol. 9:1998;757-760.
34. Giordano P., De Lucia D., Coppola B., Iolascon A. Homozygous prothrombin gene mutation and ischemic cerebrovascular disease: a case report. Acta Haematol. 102:1999;101-103.